Back to top
more

West Pharmaceutical Services (WST)

(Delayed Data from NYSE)

$318.02 USD

318.02
972,363

+0.10 (0.03%)

Updated Jul 22, 2024 04:00 PM ET

After-Market: $318.06 +0.04 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Stryker's (SYK) Q Guidance Successful in First Surgery

by Zacks Equity Research

Stryker (SYK) successfully completes first surgical case using its Q Guidance system with Cranial Guidance software. An Early Product Surveillance is underway for the combined technology.

Abbott (ABT) Reports Upbeat Cardiomems Sensor Study Result

by Zacks Equity Research

Abbott's (ABT) MONITOR-HF is the third randomized, controlled trial that will provide significant health benefits to indicated heart failure patients.

Is Nuveen ESG Mid-Cap Growth ETF (NUMG) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for NUMG

Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Here's Why Investors Should Retain STERIS (STE) Stock for Now

by Zacks Equity Research

Investors are optimistic about STERIS (STE) on strong segmental growth.

Here's Why You Should Retain Stryker (SYK) Stock for Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on the stock.

Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Stock

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.

3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about DexCom (DXCM), owing to its strong product portfolio.

ShockWave Medical (SWAV) Hits 52-Week High: Will it Continue?

by Zacks Equity Research

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.

Intuitive Surgical (ISRG) Hits 52-Week High: What's Driving It?

by Zacks Equity Research

Intuitive Surgical (ISRG) outperforms the industry and the S&P 500 Index due to its strength in robotics.

Here's Why You Should Retain Inari Medical (NARI) Stock Now

by Zacks Equity Research

Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on adoption of products is a concern.

Here's Why You Should Retain CONMED (CNMD) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about CONMED (CNMD) owing to its broad product spectrum.

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Reasons to Retain Cardinal Health (CAH) in Your Portfolio

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.

Ensign Group (ENSG) Beats on Q1 Earnings, Hikes '23 EPS View

by Zacks Equity Research

Ensign Group's (ENSG) first-quarter results benefit from growing skilled services revenues. Management estimates EPS of $4.64-$4.77 for this year, higher than the earlier mentioned $4.60-$4.74.

West Pharmaceutical (WST) Q1 Earnings Beat, Order Book Strong

by Zacks Equity Research

West Pharmaceutical's (WST) first-quarter results reflect a sustained recovery in non-COVID-19 demand amid dismal overall performance.

West Pharmaceutical Services (WST) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

West Pharmaceutical (WST) delivered earnings and revenue surprises of 18.56% and 2.78%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Industry Outlook Highlights West Pharmaceutical Services, The Cooper Companies and Henry Schein

by Zacks Equity Research

West Pharmaceutical Services, The Cooper Companies and Henry Schein have been highlighted in this Industry Outlook article.

West Pharmaceutical Services (WST) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does West Pharmaceutical Services (WST) have what it takes to be a top stock pick for momentum investors? Let's find out.

Medical Device Stocks' Q1 Earnings on Apr 27: WST, DXCM, BAX

by Zacks Equity Research

Medical Device companies' Q1 results are likely to reflect strength in customer demand. Let's see how WST, DXCM and BAX are placed ahead of their earnings releases.

3 Dental Supplies Stocks to Buy as Industry Prospects Recover

by Zacks Equity Research

Here, we discuss three stocks from the Dental Supplies industry that are likely to create wealth for investors. These include WST, COO and HSIC.

Henry Schein (HSIC) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

by Zacks Equity Research

Henry Schein (HSIC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LabCorp (LH) Misses Q1 Earnings Estimates

by Zacks Equity Research

LabCorp (LH) delivered earnings and revenue surprises of -4.26% and 0.87%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for West Pharmaceutical (WST) in Q1 Earnings?

by Zacks Equity Research

West Pharmaceutical's (WST) first-quarter 2023 results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.

BDX vs. WST: Which Stock Is the Better Value Option?

by Zacks Equity Research

BDX vs. WST: Which Stock Is the Better Value Option?